SCHEMBL558129

SCHEMBL558129

CC(C)(C)OC(=O)CCCCCCCCCCCCCCC(=O)Nc1c(C(=O)ON2C(=O)CCC2=O)cccc1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 5/20 0.40
TSHR P16473 1/20 0.37
HTR1A P08908 3/20 0.36
HTR7 P34969 3/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC3 O15379 3/20 0.34
HDAC1 Q13547 3/20 0.34
HDAC6 Q9UBN7 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927183 0.82 HSD17B10 (0.42) HDAC8TSHRHTR1AHTR7GAA
SCHEMBL557953 0.82 HSD17B10 (0.42) HDAC8TSHRHTR1AHTR7GAA
SCHEMBL1744910 0.81 HDAC8 (0.51) HDAC8HTR1AHTR7GAAHDAC3
SCHEMBL557453 0.79 HDAC8 (0.45) HDAC8HTR1AHTR7GAAKDM4E
SCHEMBL15061945 0.77 HDAC8 (0.41) HDAC8TSHRHTR1AHTR7GAA
SCHEMBL25063427 0.76 ADRA1A (0.41) TSHRGAAKDM4EHSD17B10MEN1
SCHEMBL1897841 0.75 HDAC8 (0.43) HDAC8HTR1AHTR7GAAKDM4E
SCHEMBL1676918 0.75 EPHX2 (0.39) HDAC8GAAHDAC1HDAC6HDAC2
SCHEMBL1510015 0.75 EPHX2 (0.39) HDAC8GAAHDAC1HDAC6HDAC2
SCHEMBL25434198 0.75 EPHX2 (0.39) HDAC8GAAHDAC1HDAC6HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 US disclosed
US-8476228-B2 Insulin derivatives NOVO NORDISK A/S (DK) 2013-07-02 US disclosed
US-20120035104-A1 Insulin derivatives NOVO NORDISK A/S (DK) 2012-02-09 US disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 EP disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035104-A1 Insulin derivatives IAPP, INSR, GPR119 HDAC8 1374/4885TSHR 677/4885HTR1A 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.